14,306 Shares in Johnson & Johnson (NYSE:JNJ) Purchased by U S Wealth Group LLC.

U S Wealth Group LLC. acquired a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 14,306 shares of the company's stock, valued at approximately $2,069,000.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after buying an additional 1,772,706 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock valued at $8,321,881,000 after acquiring an additional 1,561,036 shares during the last quarter. Norges Bank bought a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $4,390,037,000. Wellington Management Group LLP raised its holdings in shares of Johnson & Johnson by 1.8% during the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock valued at $3,522,447,000 after purchasing an additional 431,205 shares during the last quarter. Finally, Invesco Ltd. lifted its position in Johnson & Johnson by 6.5% during the fourth quarter. Invesco Ltd. now owns 19,126,079 shares of the company's stock valued at $2,766,014,000 after purchasing an additional 1,171,975 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of research firms have commented on JNJ. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Morgan Stanley increased their target price on Johnson & Johnson from $163.00 to $164.00 and gave the company an "equal weight" rating in a report on Wednesday. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Citigroup dropped their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a report on Wednesday, December 11th. Finally, Barclays increased their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a research report on Tuesday, January 28th. Eight equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $171.67.

Johnson & Johnson Price Performance

NYSE JNJ traded down $1.91 during trading hours on Thursday, reaching $149.06. The company's stock had a trading volume of 8,139,322 shares, compared to its average volume of 7,918,547. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm's 50-day moving average price is $159.50 and its 200-day moving average price is $155.37. The company has a market capitalization of $359.21 billion, a price-to-earnings ratio of 22.37, a PEG ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same period in the previous year, the firm posted $2.29 earnings per share. The business's revenue was up 5.3% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.